Enright Patrick G's Form 4 filing
Inozyme Pharma, Inc. (INZY) · filed Apr 21, 2022
- Accession no.
- 0000899243-22-015325
- Filed
- Apr 21, 2022, 6:04 PM ET
- Trade date
- Apr 19, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Enright Patrick GCIK 0001253886 | 10% Owner |
| Tammenoms Bakker JulietCIK 0001431159 | 10% Owner |
| Longitude Venture Partners III, L.P.CIK 0001674099 | 10% Owner |
| Longitude Capital Partners III, LLCCIK 0001713663 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2022 | Common Stock | PPurchaseAcquired | +1,355,000 | $3.69 | +$4,999,950 | 4,174,379 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.